Integrative AlphaFold Modeling, Fragment Mapping, and Microsecond Molecular Dynamics Reveal Ligand-Specific Structural Plasticity at the Human Urotensin II Receptor

preprint OA: closed CC-BY-NC-4.0

Abstract

Peptide ligands Urotensin II ( h UII, human), h UII-related peptide (URP) and its cognate human receptor ( h UT) are known for their implications in cardiovascular pathophysiology, yet the lack of experimentally resolved h UT structures has limited a deep mechanistic understanding of ligand binding and receptor activation. Here, we leverage recent breakthroughs in multistate AlphaFold predictions, long-timescale molecular dynamics (MD) simulations, and site identification by ligand competitive saturation (SILCS) based pocket mapping and solving ligand bound conformation to illuminate the dynamic interaction of h UII and URP with h UTR. By analyzing h UT dynamics in its intracellular transducer binding pocket, and residue-level interaction probabilities in each simulation, we capture subtle distinctions in the way h UII and URP anchor key pocket residues, modulate transmembrane (TM) domain tilts. Results indicate that h UII imposes stronger conformational constraints on TM5 and TM6 relative to URP, both potentially stabilizing different active-like receptor configurations. At the same time, interaction maps highlight unique aromatic and polar networks that each ligand exploits. These findings reinforce the concept that relatively small differences in GPCR peptide ligand structure may lead to large effects on receptor-state selection, signal specificity, ultimately reflecting different clinical outcomes. By integrating computational modeling with per-residue dynamics, this work not only reconciles prior mutagenesis and docking data but also provides validated 3D models and MD simulations of the endogenous ligands bound to h UT, offering new opportunities to selectively harness ligand-dependent signaling in the urotensinergic system.
Full text 1,835 characters · extracted from oa-doi-fallback · click to expand
Abstract Peptide ligands Urotensin II (hUII, human), hUII-related peptide (URP) and its cognate human receptor (hUT) are known for their implications in cardiovascular pathophysiology, yet the lack of experimentally resolved hUT structures has limited a deep mechanistic understanding of ligand binding and receptor activation. Here, we leverage recent breakthroughs in multistate AlphaFold predictions, long-timescale molecular dynamics (MD) simulations, and site identification by ligand competitive saturation (SILCS) based pocket mapping and solving ligand bound conformation to illuminate the dynamic interaction of hUII and URP with hUTR. By analyzing hUT dynamics in its intracellular transducer binding pocket, and residue-level interaction probabilities in each simulation, we capture subtle distinctions in the way hUII and URP anchor key pocket residues, modulate transmembrane (TM) domain tilts. Results indicate that hUII imposes stronger conformational constraints on TM5 and TM6 relative to URP, both potentially stabilizing different active-like receptor configurations. At the same time, interaction maps highlight unique aromatic and polar networks that each ligand exploits. These findings reinforce the concept that relatively small differences in GPCR peptide ligand structure may lead to large effects on receptor-state selection, signal specificity, ultimately reflecting different clinical outcomes. By integrating computational modeling with per-residue dynamics, this work not only reconciles prior mutagenesis and docking data but also provides validated 3D models and MD simulations of the endogenous ligands bound to hUT, offering new opportunities to selectively harness ligand-dependent signaling in the urotensinergic system. Competing Interest Statement The authors have declared no competing interest.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. This is a recent paper (2026) — citers typically take a year or two to land, and the OpenAlex reference graph may still be filling in.

Source provenance

europepmc
last seen: 2026-05-20T01:45:00.602351+00:00
unpaywall
last seen: 2026-05-26T02:00:01.498150+00:00
License: CC-BY-NC-4.0